Method of determining lipoprotein concentration in solution using light scattering

Patent metadata

Field	Value
Publication number	US-2025237603-A1
Application number	US-202519178020-A
Country	US
Kind code	A1
Filing date	Apr 14, 2025
Priority date	Dec 4, 2017
Publication date	Jul 24, 2025
Grant date	—

Abstract

The invention relates the use of single particle light scattering, preferably interferometric scattering microscopy (also referred to herein as iSCAT), to measure the concentration of a particle in a solution. The invention furthermore relates to the use of light scattering to detect lipoprotein particles in a sample, and to related diagnostic and treatment methods.

First claim

1 - 27 . (canceled)

28 . A method for detection of lipoprotein particles in a sample, comprising detecting said particles by interferometric light scattering microscopy.

29 . The method of claim 28 , wherein said detecting comprises determining the size and/or number of said particles.

30 . The method of claim 28 , comprising detecting the size and/or number of more than one different type of lipoprotein particle in said sample.

31 . The method of claim 28 , comprising detecting the ratio of different types of lipoprotein particle in said sample.

32 . The method of claim 28 , comprising detecting high density lipoprotein (HDL) particles and/or low density lipoprotein (LDL) particles.

33 . The method of claim 28 , comprising determining the ratio of HDL to LDL particles in said sample.

34 . A method for diagnosing a disease or condition associated with size and/or number of lipoprotein particles in an individual, or for determining the risk that the individual will develop said disease or condition, comprising detecting the size and/or number of lipoprotein particles in a sample from said individual by interferometric light scattering microscopy.

35 . The method of claim 34 , comprising detecting the size and/or number of more than one different type of lipoprotein particle, or the ratio of different types of lipoprotein particle, in said sample.

36 . The method of claim 34 , comprising detecting high density lipoprotein (HDL) particles and/or low density lipoprotein (LDL) particles.

37 . The method of claim 34 , comprising determining the ratio of HDL to LDL particles in said sample.

38 . The method of claim 35 , wherein a decreased number of HDL particles as compared with a control sample or reference sample/level, is indicative that the individual has said disease or condition, or has an increased risk of developing said disease or condition.

39 . The method of claim 35 , wherein an increased number and/or a decreased size of LDL particles as compared with a control sample or reference sample/level, is indicative that the individual has said disease or condition, or has an increased risk of developing said disease or condition.

40 . The method of claim 34 , wherein said disease is cardiovascular disease.

41 . The method of claim 28 , wherein said solution or sample is a biological sample, optionally obtained from a human individual.

42 . The method of claim 41 , wherein said biological sample is blood, plasma or serum, optionally obtained from a human individual.

43 . A method of selecting an individual to whom a substance or composition is to be administered, or to whom a regimen is to be prescribed, wherein said substance or composition or regimen is suitable for treating or preventing a disease or condition associated with size and/or number of lipoprotein particles, comprising detecting the size and/or number of lipoprotein particles in a sample from said individual by a method according to claim 28 , and selecting said patient for said administration or said regimen if the size and/or number of lipoprotein particles detected is indicative of the presence of said disease or condition, or of a risk thereof.

44 . A method of treating or preventing a disease or condition associated with size and/or number of lipoprotein particles in an individual, the method comprising diagnosing or determining risk of said disease or condition in said individual or selecting said individual by a method according to claim 34 , and administering a substance or composition to the individual, or carrying out a regimen thereon, which is effective to treat or prevent said disease or condition in the individual.

45 . The method of claim 28 , wherein the binding of said particles to a surface is detected.

46 . The method of claim 45 , wherein the sample is placed in a sample holder comprising said surface.

47 . The method of claim 45 , wherein absolute concentration is determined by measuring binding events between lipoprotein particles in the sample and a surface.

Assignees

• Univ Oxford Innovation Ltd

Inventors

• Andrecka Joanna
• Kukura Philipp
• Young Gavin
• Benesch Justin

Classifications

• G01N15/06

  Investigating concentration of particle suspensions (by weighing G01N5/00; investigating sedimentation of particle suspensions G01N15/04; investigating individual particles G01N15/10) · CPC title

• G01N15/0205

  by optical means · CPC title

• G01N2800/32

  Cardiovascular disorders · CPC title

• G01N2021/513

  Cuvettes for scattering measurements · CPC title

• G01N33/92 Primary

  involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)} · CPC title